Ann: PTX-200 High Overall Response in Ph2a Breast Cancer trial, page-44

I am a fan of PTX - if a biotech will be successful this one will. Yale provenance, Paul Hopper(who has had his fair share of fails too) and finding itself in the hot area of novel immunotherapy.

These results say PTX200 perhaps is effective. But as we all know, a blockbuster is not just an incremental improvement on standard of care. Are we there yet?

This is the fun of investing in this sector - if you are after growth not trading, science is your friend. Then again you can make $ whilst the turtle finally catches up to the rabbit.


GLTAH